Loading...
Loading...
Credit Suisse initiated coverage on Immunogen
IMGN with a Neutral rating and a $12 price target.
Credit Suisse noted, "We like IMGN for its expected steady cash flow from T-DM1 royalties, its antibody-drug conjugation (ADC) technology, and potential upside from a deep pipeline. However, upside to valuation requires additional drivers for which visibility is currently low."
Immunogen closed at $11.65 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in